Pfizer Licenses 3SBio’s Bispecific Antibody SSGJ-707 in Global Deal Excluding China
US major Pfizer Inc., (NYSE: PFE) this week entered into a global license agreement with...
Cancer
CSPC Pharmaceutical’s CPO301 Receives Third FDA Fast Track Designation for NSqNSCLC
China-based CSPC Pharmaceutical Group Limited (HKG: 1093) announced that its EGFR-targeted antibody-drug conjugate (ADC) CPO301...
Merck’s Keytruda Meets Primary Endpoint in Phase III Ovarian Cancer Trial
US-based Merck Sharp & Dohme Inc. (MSD; NYSE: MRK) announced positive results from the Phase...
FDA Approves Merck’s Welireg for Locally Advanced or Metastatic Pheochromocytoma and Paraganglioma
The US Food and Drug Administration (FDA) announced this week an indication extension approval for...
Novartis’ Scemblix Approved by NMPA for Newly Diagnosed Ph+ CML-CP Patients
Swiss pharmaceutical company Novartis (NYSE: NVS) announced that it has received marketing approval from China’s...
AbbVie’s Emrelis Granted FDA Accelerated Approval for NSCLC with High c-MET Overexpression
The U.S. Food and Drug Administration (FDA) has granted accelerated approval to AbbVie’s (NYSE: ABBV)...
Novartis’ Kisqali Receives NMPA Approval for High-Risk Early Breast Cancer
Switzerland-based Novartis (NYSE: NVS) announced this week that it has received another indication approval from...
CSPC Pharma Licenses Irinotecan Liposome Injection to Cipla for US Market
China-based CSPC Pharmaceutical Group Ltd. (HKG: 1093) has entered into a licensing agreement with India-headquartered...
Medilink Therapeutics Gains FDA IND Approval for VEGF-Targeted ADC YL242
Suzhou-based Medilink Therapeutics announced that it has received Investigational New Drug (IND) approval from the...
Betta Pharmaceuticals Secures Macau Approval for Ensartinib
China-based Betta Pharmaceuticals (SHE: 300558) announced a market approval filing in Macau for its ensartinib,...
RemeGen’s Disitamab Vedotin Phase III Study Meets PFS and OS Endpoints
China-based RemeGen Ltd (HKG: 9995) announced that its Phase III clinical study for the antibody...
Hengrui Pharmaceuticals Gains NMPA Clearance for SHR-1316 (sc) in ES-SCLC Trial
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that it has received clearance from...
Hansoh Pharma’s Ameile Wins Fourth NMPA Approval for NSCLC Treatment
China-based Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692) announced that its epidermal growth factor receptor...
RemeGen’s Disitamab Vedotin Receives NMPA Approval for HER2+ Breast Cancer with Liver Metastasis
China-based biopharma RemeGen Ltd (HKG: 9995) announced that the National Medical Products Administration (NMPA) has...
Hengrui Pharma Files for New Dalpiciclib Indication in Early Breast Cancer
China-based Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) announced that a new indication approval filing...
AstraZeneca’s Calquence Gains EU Approval for Mantle Cell Lymphoma
UK-based pharmaceutical major AstraZeneca (AZ; NASDAQ: AZN) announced receiving another indication approval in the European...
Huadong Medicine’s HDM2005 Receives NMPA Approval for DLBCL Clinical Trial
China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that it has received clinical trial approval...
Bayer AG Launches Phase I Study of 225Ac-GPC3 for Advanced Hepatocellular Carcinoma
German pharmaceutical giant Bayer AG (ETR: BAYN) has initiated a Phase I clinical study to...
Fosun Pharma’s Henlius Strikes Deal with Sandoz for Global Rights to HLX13 Biosimilar
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) announced that its subsidiary...
AstraZeneca’s Q1 2025 Results: 10% Revenue Growth, Oncology Segment Shines
UK-based AstraZeneca (NASDAQ: AZN) released its Q1 2025 financial results, showing a 10% year-on-year (YOY)...